Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pipecuronium Bromide

FDA-approved product (injectable, injection), marketed as Arduan.

Registered studies
5
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pipecuronium Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Pipecuronium Bromide. Its therapeutic class is shown instead.

WHO therapeutic group
Other quaternary ammonium compounds
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pipecuronium Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pipecuronium Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia

    NCT07044180 · start 2025-06-26

    Registered record
    Registry ID
    NCT07044180
    Conditions
    Neuromuscular Blocking Agents; Residual Neuromuscular Block; Reversal of Neuromuscular Blockade
    Interventions
    pipecuronium bromide; Rocuronium bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-06-26
    Completion
    2028-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blocking Agents; Residual Neuromuscular Block; Reversal of Neuromuscular Blockade
    Interventionpipecuronium bromide; Rocuronium bromide
    PhasePhase 4
    Registry statusActive not recruiting

  • Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia

    NCT07044193 · start 2025-06-26

    Registered record
    Registry ID
    NCT07044193
    Conditions
    Neuromuscular Blocking Agents; Residual Neuromuscular Block; Reversal of Neuromuscular Blockade
    Interventions
    pipecuronium bromide; Rocuronium bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-06-26
    Completion
    2028-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blocking Agents; Residual Neuromuscular Block; Reversal of Neuromuscular Blockade
    Interventionpipecuronium bromide; Rocuronium bromide
    PhasePhase 4
    Registry statusNot yet recruiting

  • Effects of Low-pressure Pneumoperitoneum Associated With Deep Pipecuronium-induced Neuromuscular Blockade on Hemodynamic Parameters for High Cardiovascular Risk Patient Undergoing General Anesthesia

    NCT06517524 · start 2023-01-08

    Registered record
    Registry ID
    NCT06517524
    Conditions
    Residual Neuromuscular Block; Cardiovascular Diseases; Neuromuscular Blockade Monitoring
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-08
    Completion
    2024-06-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResidual Neuromuscular Block; Cardiovascular Diseases; Neuromuscular Blockade Monitoring
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Anesthesia Standard Operating Procedure During On-pump Coronary Artery Bypass Grafting

    NCT05514652 · start 2018-12-01

    Registered record
    Registry ID
    NCT05514652
    Conditions
    Coronary Artery Disease; Low Cardiac Output Syndrome; Atrial Fibrillation; Postoperative Complications
    Interventions
    Low opioid anesthesia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-12-01
    Completion
    2022-12-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Low Cardiac Output Syndrome; Atrial Fibrillation; Postoperative Complications
    InterventionLow opioid anesthesia
    PhaseNot applicable
    Registry statusUnknown

  • Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade

    NCT01424488 · start 2011-09

    Registered record
    Registry ID
    NCT01424488
    Conditions
    Adult Subjects Undergoing Abdominal Surgery Under General Anesthesia
    Interventions
    sugammadex; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2012-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Subjects Undergoing Abdominal Surgery Under General Anesthesia
    Interventionsugammadex; placebo
    PhasePhase 4
    Registry statusUnknown